Clopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains… Click to show full abstract
Clopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains controversial. This study investigates whether co‐prescribing clopidogrel with PPIs is associated with a higher incidence of major adverse cardiovascular events (MACEs) compared to clopidogrel monotherapy.
Keywords:
adverse cardiovascular;
proton pump;
major adverse;
incidence major;
cardiovascular events;
pump inhibitors
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!